Why is the ResMed share price sinking again on Monday?

ResMed shares are having a very tough time this month.

| More on:
A young woman holds an open book over her head with a round mouthed expression as if to say oops as she looks at her computer screen in a home office setting with a plant on the desk and shelves of books in the background.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The ResMed Inc. (ASX: RMD) share price is having another disappointing session on Monday.

In morning trade, the sleep treatment company's shares are down 6.5% to a 52-week low of $28.70.

This means that its shares are now down 15% over the last two trading sessions following the release of a weaker-than-expected quarterly update.

Why is the ResMed share price sinking again?

Investors have been hitting the sell button today after the company's NYSE-listed shares fell more than expected on Friday night.

Each ResMed share on the NYSE represents 10 on the ASX. This means they are inextricably linked and will usually move in tow with one another.

On Friday night, the ResMed share price fell 18% to US$179.88 (including after-hours trade). This equates to A$273.28 at current exchange rates, which suggests that fair value for its locally listed shares is now $27.33.

Is this a buying opportunity?

The team at Goldman Sachs believes investors should be snapping up shares following this selloff.

While the broker was disappointed with ResMed's update, it believes that the margin weakness, which caused the earnings miss, will soon improve. Goldman said:

FY23 gross margin of 56.5% remains -330bps below FY20 levels, with a sequential deterioration of 30bps from 3Q to 4Q the primary driver of a (5)% earnings miss today (sales growth of +23% was approximately double the 10-year average).

However, in the context of various unprecedented market dynamics, the factors suppressing GM are generally understandable and likely to improve: 1) ongoing competitor challenges skewing sales mix heavily to devices over masks/consumables; 2) elevated freight costs tapering down but more slowly than anticipated; 3) component/other input cost inflation proving stubborn.

In light of this, its analysts have retained their buy rating with a $38.40 price target.

Based on the current ResMed share price, this implies a potential upside of approximately 33% for investors over the next 12 months.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group and ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Beautiful young woman drinking fresh orange juice in kitchen.
Healthcare Shares

Guess which ASX 300 stock is jumping 11% on big news

This stock is having a day to remember on Thursday. But why?

Read more »

A group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.
Healthcare Shares

Trump executive order to hit these 3 ASX pharmaceutical stocks

Donald Trump’s new executive order caused these 3 ASX pharmaceutical stocks to crash on Monday.

Read more »

Excited group of friends sitting on sofa watching sports on TV and celebrating.
Healthcare Shares

Guess which ASX 200 stock is jumping 16% on big news

Let's find out what news is getting investors excited this afternoon.

Read more »

A man slumps crankily over his morning coffee as it pours with rain outside.
Healthcare Shares

Why is this ASX 300 stock crashing 18% today?

Investors are rushing to the exits. But why? Let's look into things.

Read more »

Health professional working on his laptop.
Healthcare Shares

Are CSL shares at risk from the Trump tariffs?

How exposed are CSL shares to potential Trump medicinal tariffs?

Read more »

Donor donates blood in medical clinic. Beautiful European woman of 30 years sits in medical chair looking into camera and smiling.
Healthcare Shares

What did CSL have to say at Macquarie's 2025 conference?

Does this business have a healthy growth outlook?

Read more »

smiling health care workers in a medical setting
Healthcare Shares

Sonic Healthcare shares are down more than 40% since 2021. Will its AI initiative be the catalyst for a turnaround?

Could AI spark a recovery for this ASX healthcare stock?

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Why is this ASX All Ords stock jumping 7% today?

This stock is ending the week strongly. Let's find out what is getting investors excited.

Read more »